GSA CAPITAL PARTNERS LLP

Position in REGN — Regeneron Pharmaceuticals, Inc.

CIK 1362033 LONDON, X0

Position in REGN

as of Mar 31, 2026 · filed May 8, 2026 Compact

Position Value

$2,959,983

+$1,025,775 QoQ

Shares Held

3,831

+11.4% QoQ

Ownership

0.004%

of shares outstanding

% of Portfolio

0.21%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2020

13 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

GSA CAPITAL PARTNERS LLP holds $99,952,720 across 160 Biotechnology names. REGN ranks #1 (3.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	REGN	Regeneron Pharmaceuticals, Inc. This page	3,831	$2,959,983
2	ARDX	Ardelyx, Inc.	473,061	$2,833,635
3	NTLA	Intellia Therapeutics, Inc.	178,301	$2,285,818
4	NUVB	Nuvation Bio Inc.	495,792	$2,126,947
5	RXRX	Recursion Pharmaceuticals, Inc.	669,568	$2,055,573
6	WVE	Wave Life Sciences Ltd.	282,719	$2,049,712
7	SRPT	Sarepta Therapeutics, Inc.	90,960	$1,979,289
8	IOVA	Iovance Biotherapeutics, Inc.	557,085	$1,955,368

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$2,959,983	3,831	+11.4%	Shares	Sole	2026-05-08
2025-09-30	$1,934,208	3,440	+65.2%	Shares	Sole	2025-11-07
2025-06-30	$1,093,050	2,082	-13.5%	Shares	Sole	2025-07-22
2025-03-31	$1,527,225	2,408	+21.9%	Shares	Sole	2025-05-08
2024-12-31	$1,407,564	1,976	+212.2%	Shares	Sole	2025-02-07
2024-09-30	$665,434	633	+37.9%	Shares	Sole	2024-11-05
2023-12-31	$403,135	459	+27.9%	Shares	Sole	2024-02-16
2022-12-31	$259,014	359	-59.2%	Shares	Sole	2023-02-13
2022-09-30	$606,205	880	+66.0%	Shares	Sole	2022-11-14
2022-06-30	$313,298	530	-76.2%	Shares	Sole	2022-08-09
2021-09-30	$1,348,341	2,228	+489.4%	Shares	Sole	2021-11-12
2021-06-30	$211,128	378	-10.4%	Shares	Sole	2021-08-05
2020-03-31	$206,058	422	—	Shares	Sole	2020-05-12
No filing history on record for this holder in this stock.